Oyster Point Pharma, Inc. (OYST)
Price:
11.17 USD
( - 0 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
NEWS
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
2022-11-10 18:48:16OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Viatris (VTRS) Is Buying Oyster Point (OYST)
pulse2.com
2022-11-07 20:53:52Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
globenewswire.com
2022-11-02 16:02:00Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
globenewswire.com
2022-09-27 08:00:00Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
globenewswire.com
2022-08-25 08:00:00PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.
Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-08-13 15:45:57Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chief Business Officer Michael Campbell - Senior Vice President and Head of Commercial Conference Call Participants Patrick Dolezal - LifeSci Capital Ken Cacciatore - Cowen Joe Catanzaro - Piper Sandler Daniil Gataulin - Chardan Operator Good day, and thank you for standing by. Welcome to the Oyster Point Pharma Second Quarter 2022 Earnings Conference Call.
OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates
zacks.com
2022-08-11 18:49:20OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
globenewswire.com
2022-08-08 16:03:00Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET
Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet
zacks.com
2022-07-21 11:39:20The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Oyster Therapeutics: State Of Business Is Confounding
seekingalpha.com
2022-06-30 10:23:35OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line.
Oyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-08 05:15:38Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and CEO Dan Lochner - Chief Financial Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen and Company Chris Neyor - JPMorgan Cory Jubinville - LifeSci Capital Operator Good evening. And welcome to Oyster Point Pharma's First Quarter 2022 Earnings Conference Call.
OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2022-05-05 18:48:41OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
globenewswire.com
2022-05-03 16:01:00Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-02-27 13:35:05Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript
OYSTER PT PHARM (OYST) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2022-02-24 20:46:22OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -15.83% and 1,206.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
globenewswire.com
2022-02-16 16:05:00Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET
No data to display
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
zacks.com
2022-11-10 18:48:16OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Viatris (VTRS) Is Buying Oyster Point (OYST)
pulse2.com
2022-11-07 20:53:52Viatris (VTRS) announced it is buying Oyster Point Pharma (OYST). This is why.
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
globenewswire.com
2022-11-02 16:02:00Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
globenewswire.com
2022-09-27 08:00:00Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
globenewswire.com
2022-08-25 08:00:00PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.
Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-08-13 15:45:57Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chief Business Officer Michael Campbell - Senior Vice President and Head of Commercial Conference Call Participants Patrick Dolezal - LifeSci Capital Ken Cacciatore - Cowen Joe Catanzaro - Piper Sandler Daniil Gataulin - Chardan Operator Good day, and thank you for standing by. Welcome to the Oyster Point Pharma Second Quarter 2022 Earnings Conference Call.
OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates
zacks.com
2022-08-11 18:49:20OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
globenewswire.com
2022-08-08 16:03:00Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET
Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet
zacks.com
2022-07-21 11:39:20The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Oyster Therapeutics: State Of Business Is Confounding
seekingalpha.com
2022-06-30 10:23:35OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line.
Oyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com
2022-05-08 05:15:38Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and CEO Dan Lochner - Chief Financial Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore - Cowen and Company Chris Neyor - JPMorgan Cory Jubinville - LifeSci Capital Operator Good evening. And welcome to Oyster Point Pharma's First Quarter 2022 Earnings Conference Call.
OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2022-05-05 18:48:41OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -2.86% and 31.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
globenewswire.com
2022-05-03 16:01:00Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for May 5, 2022, 4:30 p.m. ET
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
2022-02-27 13:35:05Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript
OYSTER PT PHARM (OYST) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2022-02-24 20:46:22OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -15.83% and 1,206.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022
globenewswire.com
2022-02-16 16:05:00Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET